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A B S T R A C TObjectives: Middle-income countries often have no clear roadmap for
implementation of health technology assessment (HTA) in policy
decisions. Examples from high-income countries may not be relevant,
as lower income countries cannot allocate so much ﬁnancial and
human resources for substantiating policy decisions with evidence.
Therefore, HTA implementation roadmaps from other smaller-size,
lower-income countries can be more relevant examples for countries
with similar cultural environment and economic status.Methods: We
reviewed the capacity building process for HTA implementation in
Hungary with special focus on the role of ISPOR Hungary Chapter.
Results: HTA implementation in Hungary started with capacity build-
ing at universities with the support of the World Bank in the mid 90's,
followed by the publication of methodological guidelines for conduct-
ing health economic evaluations in 2002. The Hungarian Health
Economics Association (META) - established in 2003 - has been
recognized as a driving force of HTA implementation. META became
the ofﬁcial regional ISPOR Chapter of Hungary in 2007. In 2004 thesee front matter Copyright & 2013, International S
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ondence to: Zoltán Kaló, Faculty of Social ScienceNational Health Insurance Fund Administration made the cost-effec-
tiveness and budget impact criteria compulsory prior to granting
reimbursement to new pharmaceuticals. An Ofﬁce of Health Tech-
nology Assessment was established for the critical appraisal of
economic evaluations submitted by pharmaceutical manufacturers.
In 2010 multicriteria decision analysis was introduced for new
hospital technologies. Conclusion: The economic crisis may create
an opportunity to further strengthen the evidence base of health care
decision-making in Hungary. In the forthcoming period ISPOR Hun-
gary Chapter may play an even more crucial role in improving the
standards of HTA implementation and facilitating international col-
laboration with other CEE countries.
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The health status of the population in middle-income countries
is usually worse than in high-income countries. Because health
care resources are scarcer in these countries, the societal cost of
inappropriate pricing and reimbursement decisions of new
health care technologies is even higher. Implementation of
health technology assessment (HTA) in the decision-making
process may alleviate this problem. Key success factors for HTA
implementation, however, are building human resource and
ﬁnancial capacities, establishing a transparent decision-making
process, and implementing robust HTA methodology.
Middle-income countries often have no clear roadmap for HTA
implementation. Examples from high-income and resource-richcountries such as the United Kingdom (i.e., the “National Institute
for Health and Clinical Excellence experience”) may not be relevant
because lower income countries cannot allocate so many ﬁnancial
and human resources for substantiating health policy decisions
with evidence. In addition, the size of the country matters; the
smaller a country is the more limited facilities for preparing full
HTA reports it has. Therefore, HTA implementation roadmaps
from other smaller size, middle-income countries can be more
relevant, especially if the country is from the same geographical
and cultural environment with similar economic status.
One of the most important questions of the HTA implemen-
tation roadmap is whether capacity building should come ﬁrst
or whether mandatory HTA requirement in the reimburse-
ment process can induce the necessary background knowledge.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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disadvantages.
Previous publications have already addressed major steps of
HTA implementation in Hungary [1–3]. Because HTA implemen-
tation in Hungary started with capacity building, our objective
was to summarize the role of International Society of Pharma-
coeconomics and Outcomes Research (ISPOR) Hungary Chapter in
human resource development. The Hungarian example for HTA
capacity building can be especially relevant for other Central
Eastern European countries.
Hungary has 9.94 million inhabitants, and its gross domestic
product per capita was €10,016 in 2011 [4]; therefore, the country
has passed theWorld Bank’s threshold of high-income countries. A
major part of the HTA implementation, however, happened in the
years when Hungary was classiﬁed as a middle-income country.
Step 1: HTA Capacity Building
In the mid-1990s, two new academic centers, the School of Public
Health at the University of Debrecen and the Health Care
Management Training Center at Semmelweis University, were
established. Tutors received World Bank scholarships to study
health economics, health care management, epidemiology, bio-
statistics, public health, and other related sciences in distin-
guished international academic centers. Many graduates of the
World Bank program left the country, but many of them stayed or
even returned after some years of international experience.
Smaller scale educational projects also contributed to HTA
capacity building. The TUDOR program at the University of Szeged
was established to facilitate the application of evidence-based
medicine in Hungary. The program was sponsored by the British
Department for International Development, Know How Fund [5].
By 2000, the number of trained professionals with a thorough
understanding of HTA reached 50.
Several Hungarian universities (Corvinus University of Buda-
pest, University of Debrecen, University of Pécs, and University of
West Hungary) introduced training programs in economic eval-
uation of medical technologies for undergraduate students. The
ﬁrst postgraduate course with a major focus on economic
evaluation and economic modeling was introduced by the Fac-
ulty of Social Sciences at the Eötvös Loránd University in 2007.
By 2010, the number of trained professionals with personal
experience in HTA research or appraisal exceeded 200.
Step 2: Methodological Guidelines
Standardization of economic evaluations is a necessity prior to
mandating the use of economic evaluation in policy decisions.
The Hungarian methodological guidelines for conducting eco-
nomic evaluation of health care interventions were published in
2002 [6]. These guidelines covered all health care interventions;
therefore, they were not speciﬁc for pharmaceuticals and not
limited to reimbursement questions. The intention was to update
the guidelines every 2 years; however, the Ministry of Health did
not implement any revision before 2013.
Step 3: Scientiﬁc Organization
The Hungarian Health Economics Association (Magyar Egészség-
gazdaságtani Társaság [META]) was established in 2003. The
founders aimed at establishing an independent organization to
discuss major health economic and health policy issues at
monthly meetings. Since 2003 META has been organizing 8 to
10 meetings a year. Each 2-hour monthly meeting is dedicated to
a particular research, policy, or methodological topic, with an
advocate (or researcher), an opponent, and a moderator. Pricing
and reimbursement policy of new health technologies andmethodological standards of HTA research have been discussed
at several meetings over the years.
In 2006, META was one of the main organizers of the highly
successful 6th European Congress of Health Economics in Buda-
pest [2]. In 2007, META became the ofﬁcial Hungarian Chapter of
the ISPOR. ISPOR Hungary Chapter has a strong commitment to
facilitate international collaboration with other Central Eastern
European countries.
In 2007, ISPOR Hungary Chapter organized its ﬁrst 1-day annual
national congress in health economics. Since 2010, the 2-day con-
gress with more than 200 participants has an international plenary
session with invited speakers from other ISPOR regional chapters.
The achievements of the ISPOR Hungary Chapter have been
recognized by policymakers. Several former ministers and state
secretaries gave lectures at the annual health economics congress.
Moreover, in 2010, the State Secretary of Health invited META to
establish the Management and Health Economics Section of the
Professional Health Care College (the Advisory Board of the Health
Care Secretariat of the Ministry of Human Resources). META also
gained ofﬁcial recognition on behalf of other professional medical
societies by joining the Association of Hungarian Medical Society
(Magyar Orvostársaságok és Egyesületek Szövetsége [MOTESZ]).
In 2012, ISPOR Hungary Chapter and Eötvös Loránd University
launched a 1-week summer university course with the title of
“Implementation of HTA in CEE countries,” attended by partic-
ipants from 10 countries.
In 2013, ISPOR Hungary Chapter has 114 members, with 350
professionals visiting local meetings in 2012.
Step 4: Compulsory HTA in Policy Decisions
In 2004, the Hungarian National Health Insurance Fund Admin-
istration made the cost-effectiveness and budget impact criteria
compulsory prior to granting reimbursement to new pharmaceut-
icals. The Ministry of Health established a Department of Health
Technology Assessment (HTA Department) at one of its back-
ground institutes for the critical appraisal of economic evaluations
submitted by pharmaceutical manufacturers. The summary
appraisal prepared by the HTA Department is taken into account
by the National Health Insurance Fund Administration in reim-
bursement decisions. The single HTA process for patented out-
patient pharmaceutical products is described in Fig. 1.
Experience of the ﬁrst 6 years of the Hungarian fourth hurdle
indicated that the quality of economic evaluations submitted in
reimbursement dossiers was rather heterogeneous. In 2009, a
working group was set up to develop a policy-relevant, detailed
Hungarian critical appraisal checklist to improve the quality of
pharmacoeconomic evaluations submitted for single HTA in
pharmaceutical reimbursement applications. The critical
appraisal checklist has been published recently [7].
In 2010, new multicriteria decision analysis was introduced
for new hospital technologies, mainly for medical devices.
Recent Activities and Further Steps
ISPOR Hungary Chapter has been growing continuously. The
society has a balanced membership structure from the academia,
public, and private sectors. It has a Young Professional Unit with
an age limit of 35 years. Young professionals are especially active
in driving changes by establishing working groups in several
policy and research areas. The chapter established a student unit
for graduate, postgraduate, and PhD students in 2012.
ISPOR Hungary Chapter has coordinated the revision of
methodological guidelines for conducting economic evaluation
of health care interventions. The revised guidelines were pub-
lished in March 2013. The new guidelines indicate explicit cost-
effectiveness thresholds for Hungary (two to three times of gross
Fig. 1 – Pricing and reimbursement process with single HTA for patented outpatient pharmaceutical products. HTA, health
technology assessment.
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thresholds are considered as a tool (reference point), and so they
are not used as mandatory criterion for reimbursement. In the
new guidelines, the discount rate for both costs and health gains
has been reduced from 5% to 3.7%.
Yet, health policy and major reimbursement decisions are still
not fully transparent in Hungary. The National Health Insurance
Fund Administration has implemented serious cost-containment
measures for pharmaceuticals in recent years; therefore, budget
impact has become the most important element for reimburse-
ment decisions with mandatory ﬁnancial risk-sharing agreements.
The Young Professional Unit of ISPOR Chapter Hungary has
established a working group to develop proposals for improving
the transparency and evidence base of pharmaceutical pricing
and reimbursement decisions.Conclusions
The global economic crisis signiﬁcantly inﬂuenced the Hungarian
economy. Public health care resources are highly limited, and
they are not sufﬁcient to maintain the current health care
infrastructure and the publicly funded beneﬁt package; therefore,
health care ﬁnancing and provision have to be restructured.
There is growing pressure on policymakers to justify their major
policy decisions. The economic crisis may create an opportunity
to strengthen the evidence base of health care decision making in
Hungary [8].
ISPOR Hungary Chapter has played a crucial role in HTA
implementation. In the forthcoming period, the chapter will be mostlikely to play an evenmore crucial role in improving the standards of
HTA implementation and facilitating international collaboration with
other countries in the Central Eastern European region.
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